Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Siranomics Closes $105 Million Funding from China Investors; Plans IPO

publication date: Oct 23, 2020

Sirnaomics, a US-China company developing RNAi therapeutics, closed a $105 million Series D round from China investors. The company is developing a portfolio of novel RNAi therapeutics that address a range of diseases including various cancers, fibrosis diseases, metabolic diseases and viral infections. Earlier this year, it announced positive interim results from a Phase IIa study of STP705 for Cutaneous Squamous Cell Carcinoma in-situ. Siranomics, which plans to conduct an IPO in the near future, is headquartered in Maryland, with China operations in Suzhou and Guangzhou. More details....

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

ChinaBio® Events

ChinaBio Partnering Forum 2020

Content Availbalble Until Dec. 21, 2020